Vigorous Gainers/Losers Roundup: Alexion Pharmaceuticals (NASDAQ:ALXN), PTC Therapeutics (PTCT)

Several matter pinch shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) [Trend Analysis], as shares plunging -0.95% to $132.94 with a share volume of 1.24 Million. Alexion Pharmaceuticals Inc. (ALXN) reported, Leonard Bell, Founder of the company, has informed the Board that he will not stand for reelection as a Board member and will retire as Chairman of the Board and as a Director at the end of his term, effective as of the Annual Meeting of Shareholders slated for May 10, 2017.

The Board reported that it expects to appoint David Brennan, Alexion’s Interim CEO and fellow Board member, to succeed Bell as Chairman. Interim CEO David Brennan stated, “Since joining the Alexion Board of Directors in 2014 and being named Interim CEO late last year, I have gotten to know and deeply respect Lenny for the exceptional foresight and determination he so passionately brings to Alexion.

The Board and I look forward to partnering with Alexion’s new CEO, once he or she is reported, to continue the company’s progress and to execute on our strategy as a leader and innovator in the global biopharmaceutical industry.” The stock is going forward its 52-week low with 21.83% and moving down from its 52-week high price with -17.94%. To have technical analysis views, liquidity ratio of a company was calculated 3.10 as evaluated with its debt to equity ratio of 0.35. The float short ratio was 2.00%, as compared to sentiment indicator; Short Ratio was 1.58.

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) [Trend Analysis] runs in leading trade, it plunging -19.73% to traded at $10.58. The firm has price volatility of 9.31% for a week and 6.66% for a month. Its beta stands at 1.30 times. PTC Therapeutics Inc said that it would stop developing its cystic fibrosis drug after it failed to meet the main goal of a late-stage study. Cystic fibrosis is among the most common life-threatening genetic disorders worldwide and is caused by defects in a single gene known as the cystic fibrosis transmembrane conductance regulator. Narrow down four to firm performance, its weekly performance was -19.05% and monthly performance was -19.24%. The stock price of PTCT is moving down from its 20 days moving average with -20.53% and isolated negatively from 50 days moving average with -19.67%.


About Devon Leftovich

Leave a Reply

Your email address will not be published. Required fields are marked *